Measurement of gait speed in older adults to identify complications associated with frailty: A systematic review. Issue 6 (November 2015)

• Record Type: Journal Article
• Authors: Pamoukdjian, Frederic; Paillaud, Elena; Zelek, Laurent; Laurent, Marie; Lévy, Vincent; Landre, Thierry; Sebbane, Georges
• Is Part Of: Journal of geriatric oncology. Volume 6:Issue 6(2015)
• Page Start: 484
• Page End: 496
• Publication Date: 2015-11
• Subjects: Gait speed -- Elderly -- Frailty -- Comprehensive geriatric assessment -- Cancer -- Screening test; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2015.08.006
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Several frailty screening tests in older cancer patients were developed but their statistical performance is low. We aimed to assess whether measurement of usual gait speed (GS) alone could be used as a frailty screening test in older cancer patients. This systematic review was conducted on "pub med" between 1984 and 2014 and included reviews and original studies. Eligibility criteria were: GS over a short distance, alone or included in composite walking tests (Timed Get Up and Go test: TGUG, Short Physical Performance Battery: SPPB) in older people (aged 65 and over) living in a community setting and predictive value of GS on medical complications associated with frailty. 46 articles were finally selected. GS alone is consensual and recommended for screening sarcopenia in elderly. A slow GS is predictive of early death, disability, falls and hospitalization/institutionalization in older people living in a community setting. GS alone is comparable to composite walking tests that do not provide additional information on the medical complications associated with frailty. Despite few studies in geriatric oncology, GS seems to predict overall survival and disability. We suggest GS over 4 m (at a threshold of 1 m/s) as a new frailty screening test in older cancer patients (65 and over) to guide the implementation of a comprehensive geriatric assessment during the initial management phase or during follow-up. Prospective cohort studies are needed to validate this algorithm and compare it with other screening tool.